Strategies to prevent opioid misuse, abuse, and diversion that may also reduce the associated costs

American Health and Drug Benefits

Volumn 4, Issue 2, 2011, Pages 107-114

  Hahn, Kathryn L ^a  

^a OREGON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUROX; HYDROCODONE; METHADONE; NARCOTIC ANALGESIC AGENT; OXYCODONE; UNCLASSIFIED DRUG;

ANALGESIA; CHRONIC PAIN; CONTROL STRATEGY; COST CONTROL; DRUG CONTROL; DRUG FORMULATION; DRUG MISUSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HEALTH CARE PLANNING; HEALTH CARE PRACTICE; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; MEDICAL EDUCATION; MEDICAL ERROR; MEDICAL SPECIALIST; OPIATE ADDICTION; PATIENT EDUCATION; PATIENT IDENTIFICATION; PATIENT REFERRAL; PHARMACY; PRESCRIPTION; REVIEW; RISK REDUCTION; SCREENING TEST; STRATEGIC PLANNING; TREATMENT OUTCOME; UNITED STATES; URINALYSIS;

EID: 79956005299     PISSN: 19422962     EISSN: 19422970     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration. Results from the 2007 National Survey on Drug Use and Health: national findings. Rockville, MD; 2008. DHHS Publication No. (SMA) 08-4343. http://oas.samhsa.gov/nsduh/2k7nsduh/2k7Results.pdf. Accessed August 14, 2008.
2. US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration. Drug Abuse Warning Network, 2006: national estimates of drug-related emergency department visits. Rockville, MD; 2008. DAWN Series D-30; DHHS Publication No. (SMA) 08-4339. http://dawninfo.samhsa.gov/files/ED2006/DAWN2k6ED.pdf. Accessed October 15, 2009.
3. US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration. Treatment episode data set (TEDS) 1996-2006. National admissions to substance abuse treatment services. Rockville, MD; 2008. DASIS Series S-43, DHHS Publication No. (SMA) 08-4347. http://wwwdasis.samhsa.gov/teds06/teds2k6aweb508.pdf. Accessed July 29, 2009.
4. US Food and Drug Administration Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for industry: development and use of risk minimization action plans. March 2005. www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126830.pdf. Accessed February 25, 2011.
5. US Food and Drug Administration Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for industry: premarketing risk assessment. March 2005. www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm126958.pdf. Accessed February 25, 2011.
6. US Food and Drug Administration Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for industry: good pharmacovigilance practices and pharmacoepidemiologic assessment. March 2005. www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126834.pdf. Accessed February 25, 2011.
7. Food and Drug Administration Amendments Act of 2007, Public Law 110-85, Food and Drug Administration. September 27, 2007.
8. Johnston LD, O' Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings, 2007. Bethesda, MD: National Institute on Drug Abuse; 2008. NIH Publication No. 08-6418. www.monitoringthefuture.org/pubs/monographs/overview2007.pdf. Accessed July 14, 2010.
9. Hays LR. A profile of OxyContin addiction. J Addict Dis. 2004;23:1-9.
10. Carise D, Dugosh KL, McLellan AT, et al. Prescription OxyContin abuse among patients entering addiction treatment. Am J Psychiatry. 2007;164:1750-1756.
11. Butler SF, Budman SH, Licari A, et al. National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse. Pharmacoepidemiol Drug Saf. 2008;17:1142-1154.
12. Raffa RB, Pergolizzi JV Jr. Opioid formulations designed to resist/deter abuse. Drugs. 2010;70:1657-1675.
13. Compton WM, Volkow ND. Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend. 2006;83(suppl 1):S4-S7.
14. Colliver JD, Kroutil LA, Dai L, Gfroerer JC. Misuse of prescription drugs: data from the 2002, 2003, and 2004 national surveys on drug use and health. Rockville, MD: US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies; 2006. DHHS Publication No. (SMA) 06-4192, Analytic Series A-28. www.oas.samhsa.gov/prescription/toc.htm. Accessed October 9, 2008.
15. Fishbain DA, Cole B, Lewis J, et al. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med. 2008;9:444-459.
16. Manchikanti L, Cash KA, Damron KS, et al. Controlled substance abuse and illicit drug use in chronic pain patients: an evaluation of multiple variables. Pain Physician. 2006;9:215-225.
17. Ives TJ, Chelminski PR, Hammett-Stabler CA, et al. Predictors of opioid misuse in patients with chronic pain: a prospective cohort study. BMC Health Serv Res. 2006;6:46.
18. Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS. Validity of self-reported drug use in chronic pain patients. Clin J Pain. 1999;15:184-191.
19. Michna E, Jamison RN, Pham LD, et al. Urine toxicology screening among chronic pain patients on opioid therapy: frequency and predictability of abnormal findings. Clin J Pain. 2007;23:173-179.
20. Manchikanti L, Singh A. Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician. 2008;11(2 suppl):S63-S88.
21. Paulozzi LJ, Budnitz DS, Xi Y. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf. 2006;15:618-627.
22. White AG, Birnbaum HG, Mareva MN, et al. Direct costs of opioid abuse in an insured population in the United States. J Manag Care Pharm. 2005;11:469-479.
23. Birnbaum HG, White AG, Reynolds JL, et al. Estimated costs of prescription opioid analgesic abuse in the United States in 2001: a societal perspective. Clin J Pain. 2006;22:667-676.
24. Paulozzi LJ, Xi Y. Recent changes in drug poisoning mortality in the United States by urban-rural status and by drug type. Pharmacoepidemiol Drug Saf. 2008; 17:997-1005.
25. Coalition Against Insurance Fraud. Prescription for peril: how insurance fraud finances theft and abuse of addictive prescription drugs. Washington, DC; 2007. www.insurancefraud.org/drugDiversion.htm. Accessed August 25, 2008.
26. Wang J, Christo PJ. The influence of prescription monitoring programs on chronic pain management. Pain Physician. 2009;12:507-515.
27. Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med. 2005;6:107-112.
28. Gourlay D, Heit H. Universal precautions: a matter of mutual trust and responsibility. Pain Med. 2006;7:210-211.
29. Substance Abuse and Mental Health Services Administration. Screening, brief intervention, and referral to treatment: new populations, new effectiveness data. November/December 2009. www.samhsa.gov/samhsanewsletter/Volume_17_Number_6/SBIRT.aspx. Accessed March 14, 2011.
30. Fishman SM, Bandman TB, Edwards A, Borsook D. The opioid contract in the management of chronic pain. J Pain Symptom Manage. 1999;18:27-37.
31. National Alliance for Model State Drug Laws. Status of prescription drug monitoring programs. March 7, 2011. www.namsdl.org/documents/StatusofStatesMarch72011.pdf. Accessed March 14, 2011.
32. Katz N, Panas L, Kim M, et al. Usefulness of prescription monitoring programs for surveillance-analysis of Schedule II opioid prescription data in Massachusetts, 1996-2006. Pharmacoepidemiol Drug Saf. 2010;19:115-123.
33. US Drug Enforcement Administration. Electronic prescriptions for controlled substances. Docket No. DEA-218I; RIN 1117-AA61. Federal Register. 2010;75: 16236-16319.
34. Lohr M. House Bill No. 964. Commonwealth of Virginia General Assembly; February 18, 2010. http://leg1.state.va.us/cgi-bin/legp504.exe?101+ful+HB964H1. Accessed May 21, 2010.
35. United States Government Accountability Office. Medicaid fraud and abuse related to controlled substances identified in selected states. Report to Congressional Requestors. September 2009. GAO-09-957. www.smpresource.org/Content/NavigationMenu/HealthCareFraud/Medicaid/GAO_Medicaid_controlled_substances.pdf. Accessed May 11, 2010.
36. Pharmacy Voice. FDA: Reformulated OxyContin may be less prone to abuse. April 7, 2010. http://nacds.rxpost.net/News/article.cfm?Article_ID=561428. Accessed March 14, 2011.
37. Comer SD, Sullivan MA, Vosburg SK, et al. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. Addiction. 2010;105:709-718.
38. Stauffer J, Setnik B, Sokolowska M, et al. Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extendedrelease capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study. Clin Drug Investig. 2009;29:777-790.
39. Acura Pharmaceuticals. Acurox with Niacin tablets. 2010. http://acurapharm.com/products/acurox-tablets/. Accessed May 11, 2010.
40. ClinicalTrials. gov. Study of the abuse liability of oxycodone HCl/niacin in subjects with a history of opioid abuse. October 22, 2008. Identifier NCT00699010. www.clinicaltrials.gov/ct2/show/NCT00699010?term=acurox&rank=2. Accessed May 11, 2010.
41. Acura Pharmaceuticals. Study AP-ADF-102. 2010. http://acurapharm.com/products/acurox-tablets/study-ap-adf-102/. Accessed May 11, 2010.
42. Shibuya RB. History of Oxycontin: labeling and risk management program. US Food and Drug Administration Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees; November 13-14, 2008.
43. Simojoki K, Vorma H, Alho H. A retrospective evaluation of patients switched from buprenorphine (Subutex) to the buprenorphine/naloxone combination (Suboxone). Subst Abuse Treat Prev Policy. 2008;3:16.
44. National Drug Intelligence Center. Intelligence bulletin: buprenorphine: potential for abuse. September 2004. Document ID: 2004-L0424-013. www.justice.gov/ndic/pubs10/10123/index.htm. Accessed May 11, 2010.
45. Wong LL, for the US Drug Enforcement Administration Office of Diversion Control. Buprenorphine in the treatment of opioid addiction: reassessment 2010. Presented at the SAMHSA National Advisory Council. Washington, DC; May 11-12, 2010. http://buprenorphine.samhsa.gov/bwns/2010_presentations_pdf/10a_10b_508.pdf. Accessed June 14, 2010.
46. Smith MY, Bailey JE, Woody GE, Kleber HD. Abuse of buprenorphine in the United States: 2003-2005. J Addict Dis. 2007;26:107-111.
47. Bruce RD, Govindasamy S, Sylla L, et al. Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market. Am J Drug Alcohol Abuse. 2009;35:68-72.